• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受胰酶替代疗法的囊性纤维化患者的住院率。

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy.

作者信息

Trapnell Bruce C, Chen Su, Khurmi Rupal, Bodhani Amit, Kapoor Mudra, Haupt Mark

机构信息

Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

AbbVie Inc., North Chicago, IL, USA.

出版信息

Chron Respir Dis. 2020 Jan-Dec;17:1479973119900612. doi: 10.1177/1479973119900612.

DOI:10.1177/1479973119900612
PMID:31984768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6985972/
Abstract

We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000-2012) and 13,989 adults (2000-2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly ( < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults ( < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients.

摘要

我们调查了有胰酶替代疗法(PERT)使用记录的囊性纤维化(CF)患者自我报告的PERT依从性、营养状况与全因住院之间的关系。对来自CF基金会患者登记处的5301名儿童(2000 - 2012年)和13989名成人(2000 - 2013年),分析了自我报告的年度PERT使用率(依从性)与年度住院率(HAR)和年度总住院天数(THNs)之间的关联。采用多变量线性回归来确定HAR和THN与平均年度PERT使用率、累积PERT使用率、平均体重指数(BMI)(成人)或BMI百分位数(儿童)、年龄和性别的关联。儿童的年度PERT使用率中位数为87%,成人为80%。在统计学上,较高的年度PERT使用率、较长的累积PERT使用时间以及较高的BMI百分位数(儿童)或BMI(成人)与儿童和成人较低的年度HAR以及较少的年度THN显著相关(<0.0001)。在儿童和成人中,女性性别与较高的年度HAR和较多的年度THN相关(<0.05)。结果表明,自我报告的PERT依从性、BMI增加以及男性性别与CF患者较少的住院次数和年度住院天数相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/59ee08e5f736/10.1177_1479973119900612-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/725d0ff14dd7/10.1177_1479973119900612-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/15c583eb8805/10.1177_1479973119900612-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/59ee08e5f736/10.1177_1479973119900612-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/725d0ff14dd7/10.1177_1479973119900612-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/15c583eb8805/10.1177_1479973119900612-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8cf/6985972/59ee08e5f736/10.1177_1479973119900612-fig3.jpg

相似文献

1
Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy.接受胰酶替代疗法的囊性纤维化患者的住院率。
Chron Respir Dis. 2020 Jan-Dec;17:1479973119900612. doi: 10.1177/1479973119900612.
2
Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis of the US and UK cystic fibrosis registries.依伐卡托特获批后胰腺酶处方:美国和英国囊性纤维化注册研究的回顾性分析。
J Cyst Fibros. 2024 Jul;23(4):746-753. doi: 10.1016/j.jcf.2024.01.011. Epub 2024 Feb 10.
3
Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines.囊性纤维化儿科患者的营养状况、营养摄入及酶补充剂的使用;一项参照现行指南的欧洲多中心研究
J Cyst Fibros. 2017 Jul;16(4):510-518. doi: 10.1016/j.jcf.2017.03.005. Epub 2017 Mar 17.
4
Meal patterns, dietary fat intake and pancreatic enzyme use in preadolescent children with cystic fibrosis.患有囊性纤维化的青春期前儿童的饮食模式、膳食脂肪摄入量及胰酶使用情况
J Pediatr Gastroenterol Nutr. 2006 Nov;43(5):651-9. doi: 10.1097/01.mpg.0000234082.47884.d9.
5
Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis.胰腺酶替代疗法剂量与囊性纤维化患儿营养结局的关系。
J Pediatr. 2014 May;164(5):1110-1115.e1. doi: 10.1016/j.jpeds.2014.01.022. Epub 2014 Feb 20.
6
Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study.囊性纤维化成人胰腺酶替代治疗摄入的相关因素:一项横断面研究的结果。
Nutrients. 2022 Mar 22;14(7):1330. doi: 10.3390/nu14071330.
7
Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis.使用移动应用程序进行胰腺酶替代治疗的自我管理与囊性纤维化儿童胃肠相关生活质量的改善相关。
J Cyst Fibros. 2020 Jul;19(4):562-568. doi: 10.1016/j.jcf.2020.04.001. Epub 2020 Apr 22.
8
Preliminary report of the (13)C-mixed triglyceride breath test to assess timing of pancreatic enzyme replacement therapy in children with cystic fibrosis.用于评估囊性纤维化患儿胰酶替代疗法时机的(13)C混合甘油三酯呼气试验初步报告
J Cyst Fibros. 2016 Sep;15(5):669-74. doi: 10.1016/j.jcf.2016.03.008. Epub 2016 Apr 19.
9
Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis.基于食物特性调整囊性纤维化患者胰酶补充剂剂量的循证方法的临床评估
J Cyst Fibros. 2021 Sep;20(5):e33-e39. doi: 10.1016/j.jcf.2020.11.016. Epub 2020 Dec 2.
10
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption.囊性纤维化患者的胰酶替代疗法:剂量、变异性及脂肪吸收系数
Rev Esp Enferm Dig. 2017 Oct;109(10):684-689. doi: 10.17235/reed.2017.4951/2017.

引用本文的文献

1
Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine.个性化医疗时代囊性纤维化患儿外分泌性胰腺功能不全的当前及未来治疗方法
Pharmaceutics. 2023 Jan 3;15(1):162. doi: 10.3390/pharmaceutics15010162.
2
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.一项针对伴有肺部恶化的囊性纤维化患者的抗菌疗程随机试验中的医疗保健成本。
J Cyst Fibros. 2022 Jul;21(4):594-599. doi: 10.1016/j.jcf.2022.03.001. Epub 2022 Mar 14.
3
Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial.

本文引用的文献

1
Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.囊性纤维化患者的肠内管饲:囊性纤维化基金会循证指南
J Cyst Fibros. 2016 Nov;15(6):724-735. doi: 10.1016/j.jcf.2016.08.004. Epub 2016 Sep 3.
2
ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.欧洲临床营养与代谢学会(ESPEN)、欧洲儿科胃肠病学、肝病学和营养学会(ESPGHAN)以及欧洲囊性纤维化协会(ECFS)关于囊性纤维化婴儿、儿童和成人营养护理的指南。
Clin Nutr. 2016 Jun;35(3):557-77. doi: 10.1016/j.clnu.2016.03.004. Epub 2016 Mar 15.
3
Parental Depression and Pancreatic Enzymes Adherence in Children With Cystic Fibrosis.
囊性纤维化患者使用无胰酶营养补充剂的肠道脂质吸收:一项随机、双盲、交叉先导试验。
Nutrients. 2022 Feb 5;14(3):680. doi: 10.3390/nu14030680.
4
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.杂合 F508del 和最小功能突变的囊性纤维化患者的疾病负担。
J Cyst Fibros. 2022 Jan;21(1):96-103. doi: 10.1016/j.jcf.2021.07.003. Epub 2021 Jul 19.
囊性纤维化患儿的父母抑郁与胰酶依从性
Pediatrics. 2016 Feb;137(2):e20152296. doi: 10.1542/peds.2015-2296. Epub 2016 Jan 5.
4
Cystic fibrosis genetics: from molecular understanding to clinical application.囊性纤维化遗传学:从分子理解到临床应用
Nat Rev Genet. 2015 Jan;16(1):45-56. doi: 10.1038/nrg3849. Epub 2014 Nov 18.
5
Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy.囊性纤维化中的消化系统功能障碍:营养治疗面临的挑战
Dig Liver Dis. 2014 Oct;46(10):865-74. doi: 10.1016/j.dld.2014.06.011. Epub 2014 Jul 19.
6
Pulmonary medication adherence and health-care use in cystic fibrosis.囊性纤维化患者的肺部药物治疗依从性和医疗保健使用情况。
Chest. 2014 Jul;146(1):142-151. doi: 10.1378/chest.13-1926.
7
Update on key emerging challenges in cystic fibrosis.囊性纤维化新出现的关键挑战最新情况
Med Princ Pract. 2014;23(5):393-402. doi: 10.1159/000357646. Epub 2014 Jan 10.
8
Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis.预测儿童囊性纤维化患者初始 1 秒用力呼气容积低的因素及其结果。
J Pediatr. 2014 Apr;164(4):832-8. doi: 10.1016/j.jpeds.2013.11.064. Epub 2014 Jan 10.
9
Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.与囊性纤维化患者 FEV1 下降相关的因素:对 ECFS 患者注册中心的分析。
Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.
10
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.了解囊性纤维化护理的成本:按年龄和健康状况分析。
Value Health. 2013 Mar-Apr;16(2):345-55. doi: 10.1016/j.jval.2012.12.003.